Drug Development

VaxGen publishes phase 1 clinical trial results on anthrax vaccine candidate in Vaccine

Published in Vaccine Weekly, September 13th, 2006

VaxGen, Inc. (VXGN.PK) announced that peer-reviewed data from the company's phase 1 clinical trial of its candidate anthrax vaccine rPA102 were published in the journal Vaccine.

The paper, titled "Immunogenicity and Tolerance of Ascending Doses of a Recombinant Protective Antigen (rPA102) Anthrax Vaccine: A Randomized, Double-blinded, Controlled, Multicenter Trial," presents data which demonstrated a clear relationship between the rPA102 dose administered and the subsequent immune response. All injections were administered 4 weeks apart and at each dose level examined, three injections of the vaccine candidate yielded higher antibody titers than with two...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-09-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry